A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease

A prospective multicenter comparative clinical trial between corticosteroid pulse therapy vs. combination therapy of oral corticosteroid and cyclosporine on Vogt-Koyanagi-Harada disease - A comparative study between steroid-pulse therapy vs. orla steroid+cyclosporine combination theray on VKH disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014387

Enrollment

Registered

2014-06-27

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vogt-Koyanagi- Harada disease

Interventions

1.Steroid monotherapy group methyl predonisolone (mPSL) 1000mg per day, intravenous infusion for 3 days The oral PSL (either a daily dose of 1mg/kg or 60mg for 2 weeks PSL will be tapered with decr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with VKH disease with active uveitis within 2 months after disease onset. Patients should meet the International Revised Criteria for VKH disease. In addition, patients must have at least one systemic symptome tipically seen in VKH disease.

Exclusion criteria

Exclusion criteria: 1. Systemic steroids within 90 days 2. Abnormal values of complete blood counts 3. Abnormal liver enzymes and renal function 4. Infectious diseases(ex.tuberculosis, hepatitis B, hepatitis C, syphilis etc.) 5. Those who have diseases in which corticosteroids and cyclosporine are contraindication. 6. Those who are being treated with immune suppression agents other than prednisolone 7. Investigators declare a subject ineligible for any sound reasons

Design outcomes

Primary

Measure	Time frame
The efficacy to prevent recurrances of uveitis and systemic inflammation of VKH disease, safety at one year after the initiation of therapies	—

Countries

Japan

Contacts

Public ContactTakashi Komizo

Miyata Eye Hospital Medical office

komizo@miyata-med.ne.jp0986-22-1441

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026